[Experimental BCSC-1 gene therapy on nasopharyngeal carcinoma mediated by adenovirus].
OBJECTIVE
To explore the therapeutic value of BCSC-1 in tumor gene therapy.


METHODS
Recombinant adenovirus Ad5-BCSC-1 was prepared. Cell proliferation was assayed using CellTiter 96 Aqueous one solution cell proliferation assay kit. Ad5-BCSC-1 was injected into tumor with Ad5-egfp or with PBS injection as controls. The injections were repeated one weak later. After another 2 weeks, the mice were sacrificed and the tumors were excised and weighed.


RESULTS
The growth of the CNE-2L2 cell infected with Ad5-BCSC-1 in vitro was remarkably slower than that of the controls, the wild type cell and the cell infected with Ad5-egfp. In contrast to the controls, the cells infected with Ad5-BCSC-1 aggregated and formed huge messes in the culture. The average weight of the CNE-2L2 tumors in mice was (2.28 +/- 0.73), (2.07 +/- 0.40), and (0.58 +/- 0.32) g for the tumors injected with PBS, Ad5-egfp, and Ad5-BCSC-1, respectively (Ad5-BCSC-1 vs. PBS or Ad5-egfp, P<0.05).


CONCLUSIONS
Intra-tumor injection of Ad5-BCSC-1 can suppress the growth of CNE-2L2 tumor in nude mice, suggesting that BCSC-1 gene therapy may be effective for tumors with low or no expression of BCSC-1 gene.
Zhou
Yi-Qun
YQ
Department of Immunology, Institute of Basic Medical Sciences, CAMS and PUMC, Beijing 100005, China.
Ju
Ji-Yu
JY
Tian
Yun
Y
Liu
Yin
Y
Zhu
Li-Ping
LP
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D002277:Carcinoma / Q000235:genetics / Q000628:therapy*; D045744:Cell Line, Tumor; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009303:Nasopharyngeal Neoplasms / Q000235:genetics / Q000628:therapy*; D009363:Neoplasm Proteins / Q000235:genetics / Q000502:physiology*; D023041:Xenograft Model Antitumor Assays
D009363:Neoplasm Proteins; C109969:VWA5A protein, human